EQS-News: Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

Issuer: Immunic, Inc. / Key word(s): Study Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis 17.08.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Completes Enrollment of Its P...

Related Keywords

Ukraine ,United States ,Russia ,America ,Jessica Breu ,Daniel Vitt ,Edna Kaplan ,Paula Schwartz ,Andreas Muehler ,Exchange Commission ,Immunic Inc ,Nasdaq ,Distribution Services ,Rx Communications Group ,Completes Enrollment ,Its Phase ,Vidofludimus Calcium ,Progressive Multiple Sclerosis ,Progressive Multiple ,Unblinded Interim Biomarker Analysis Expected ,Full Data Readout Expected ,Chief Executive Officer ,Chief Medical Officer ,North America ,Eastern Europe ,Private Securities Litigation Reform Act ,Annual Report ,Investor Relations ,Corporate News ,Regulatory Announcements ,Its ,Hase ,Calliper ,Trial ,Idofludimus ,Calcium ,Progressive ,Multiple ,Clerosis ,Et Cest ,The ,Ompletes ,Enrollment ,P ,